Preimplantation Genetic Diagnosis May Pose Neurological Risks
By Medical News Today,
Medical News Today
| 07. 23. 2009
Preimplantation genetic diagnosis (PGD) has helped many couples conceive healthy children and is generally considered a safe practice. However, a new long-term analysis of PGD in mice suggests that this procedure may increase risks of weight gain and memory decline in adulthood.
PGD is used alongside assisted reproduction technologies to ensure couples that may be carriers of genetic disease (e.g. Ashkenazi Jews who have a high incidence of Tay-Sachs among their population) don't pass on defective genes to their children. While PGD is not believed to pose any serious health risks, the procedure does involve manipulating the developing embryo and no rigorous long-term studies have been carried out.
Ran Huo, Qi Zhou and colleagues used a mouse model to examine how a blastomere biopsy, as the key manipulation during the PGD procedure, could affect fetal, neonatal and adult development.
They found that there were no differences in embryo development prior to uterine implantation in the biopsied and control groups, which is consistent with results found in humans. However, following implantation, successful births from biopsied embryos were significantly lower than in...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...